Clinical significance of Ki-67 labeling index in pituitary macroadenoma
- PMID: 15953875
- PMCID: PMC2782209
- DOI: 10.3346/jkms.2005.20.3.489
Clinical significance of Ki-67 labeling index in pituitary macroadenoma
Abstract
The aim of our study was to investigate the correlation of the proliferative activity of pituitary neoplasms with clinical characteristics and recurrences. Tumor specimens were obtained from 44 consecutive patients with pituitary macroadenomas who underwent surgery between July 1998 and August 2003. Specimens were immediately fixed in 10% buffered formalin and then embedded in paraffin. The Ki-67 antigen was assessed by immumohistochemical analysis using the monoclonal antibody. We investigated the correlation of the Ki-67 labeling index with the following clinical and radiological characteristics: sex, age, presence or absence visual field defect, tumor classification, maximal tumor diameter, Hardy's classification, type of tumor, invasiveness, and recurrence. Our study suggests that the clinical characteristics such as visual field defect and recurrence are correlated with the high Ki-67 labeling index. No statistical differences were observed in the Ki-67 labeling index in relation to the following characteristics: sex, age, tumor classification, maximal tumor diameter, Hardy's classification, type of tumor, and invasiveness into the sphenoid sinus or cavernous sinus.
Figures


Similar articles
-
Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.Neurosurgery. 2000 Dec;47(6):1313-8; discussion 1318-9. Neurosurgery. 2000. PMID: 11126902
-
The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.Endocr Pathol. 2019 Mar;30(1):49-55. doi: 10.1007/s12022-018-9563-2. Endocr Pathol. 2019. PMID: 30610566
-
Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.Neurol India. 2001 Jun;49(2):144-7. Neurol India. 2001. PMID: 11447433
-
Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.Neurol Res. 2010 Dec;32(10):1060-71. doi: 10.1179/016164110X12670144737855. Epub 2010 May 18. Neurol Res. 2010. PMID: 20483025 Review.
-
Relevance of high Ki-67 in pituitary adenomas. Case report and review of the literature.Neurosurg Focus. 2005 Nov 15;19(5):E11. doi: 10.3171/foc.2005.19.5.12. Neurosurg Focus. 2005. PMID: 16398461 Review.
Cited by
-
Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up.Int J Endocrinol. 2016;2016:7964523. doi: 10.1155/2016/7964523. Epub 2016 Aug 18. Int J Endocrinol. 2016. PMID: 27635138 Free PMC article.
-
Phosphorylation of cAMP response element binding protein (CREB) as a marker of hypoxia in pituitary adenoma.J Neurooncol. 2006 Sep;79(2):143-50. doi: 10.1007/s11060-006-9131-3. Epub 2006 Apr 6. J Neurooncol. 2006. PMID: 16598418
-
Associations of Ki-67 Labeling Index with Clinical and Paraclinical Features of Growth Hormone-Secreting Pituitary Adenomas: A Single Center Report from Iran.Int J Endocrinol Metab. 2019 Apr 13;17(2):e81983. doi: 10.5812/ijem.81983. eCollection 2019 Apr. Int J Endocrinol Metab. 2019. PMID: 31372169 Free PMC article.
-
The clinical significance of MIB-1 labeling index in pituitary adenomas.Pituitary. 2010 Dec;13(4):337-44. doi: 10.1007/s11102-010-0242-7. Pituitary. 2010. PMID: 20640601
-
The Past, Present, and Future Statuses of Formerly Classified "Atypical Pituitary Adenomas": A Clinicopathological Assessment of 101 Cases in a Cohort of More than 1,000 Pure Endoscopically Treated Patients in Single Center.J Neurol Surg B Skull Base. 2021 Jul;82(Suppl 3):e94-e100. doi: 10.1055/s-0040-1702219. Epub 2020 Feb 20. J Neurol Surg B Skull Base. 2021. PMID: 34306922 Free PMC article.
References
-
- Pizaro CB, Oliveira MC, Coutinho LB, Ferreira NP. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res. 2004;37:235–243. - PubMed
-
- Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M. Proliferation index of non-functioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosugery. 2000;47:1313–1319. - PubMed
-
- Sassolas G, Trouillas J, Treluyer C, Perrin G. Management of non-functioning pituitary adenomas. Acta Endocrinol (Copenh) 1993;129:21–26. - PubMed
-
- Petruson B, Jakobsson KE, Elfverson J, Bengtsson BA. Five-year follow-up of nonsecreting pituitary adenomas. Arch Otolaryngol Head Neck Surg. 1995;121:317–322. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical